Renal Cell Cancer Flashcards

You may prefer our related Brainscape-certified flashcards:
1
Q

Management of small renal cortical tumours <3cm?

A

RFA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Which imaging should be included for staging of RCC?

A

CT head, CT TAP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the indications for adjuvant SACT in RCC?

A

High risk i.e. T2 (at least 7cm) G4 or sarcomatoid features, T3 or T4 or node positive or M1 following metastatectomy with no residual disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Most common sites of metastatic disease in RCC?

A

LN, lung, bone, brain, liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Which features are associated with good outcomes in management of oligometastatic disease?

A

Long DFI, pulmonary mets, Age <60yrs and good PS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the Heng score (MDC score)? Name the features (6)

A

<1 yr since diagnosis to systemic treatment
KPS <80
Hypercalcaemia
Hb <ULN>ULN
Neuts >ULN</ULN>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How many points on Heng score for favourable, intermediate and poor

A

0= favourable, 1-2= intermediate, >2 = poor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

When is ipi/nivo licensed in the first line?

A

In intermediate and poor risk group

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

When would you be more likely to use immunotherapy plus TKI in the first line (i.e. pem/len or nivo/cabo?

A

In high volume and high risk disease where a rapid response is needed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Do sarcomatoid type RCC have a better or worse response to immunotherapy?

A

Better response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Second line treatment when combination IO or IO/TKI used in first line?

A

Lenvatinib and Everolimus (can use if only 1 TKI used previously)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Third line options?

A

Cabozantinib, sunitinib or axitinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Who is the typical patient to develop medullary renal cancer?

A

Young patients with sickle cell traits, typically presents with early visceral involvement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Management of metastatic papillary renal cancer?

A

Cabozantanib, poor response to IO.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is most likely pathogenesis in the development of clear cell renal cancer?

A

Up regulated expression of HIF- controlled genes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the mainstay of treatment for Adrenocortical carcinoma for a curative approach?

A

Complete en bloc resection of ACC is the mainstay, pre-op biopsy to confirm suspected ACC is not necessary.

17
Q

What is the mOS for patients with poor risk RCC?

A

<12m

18
Q

Renal medullary carcinoma is most commonly associated with which mutation?

A

SMARCB1